WO1996030390A3 - METHOD FOR PREPARING 17α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE METHOD, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES. - Google Patents

METHOD FOR PREPARING 17α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE METHOD, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES. Download PDF

Info

Publication number
WO1996030390A3
WO1996030390A3 PCT/US1996/003660 US9603660W WO9630390A3 WO 1996030390 A3 WO1996030390 A3 WO 1996030390A3 US 9603660 W US9603660 W US 9603660W WO 9630390 A3 WO9630390 A3 WO 9630390A3
Authority
WO
WIPO (PCT)
Prior art keywords
intermediates
preparation
methods
norpregna
dimethylaminophenyl
Prior art date
Application number
PCT/US1996/003660
Other languages
French (fr)
Other versions
WO1996030390A2 (en
Inventor
Hyun K Kim
Pemmaraju Narasinha Rao
James E Burdett Jr
Carmie Kirk Acosta
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Priority to EP96909749A priority Critical patent/EP0817793A2/en
Priority to AU53145/96A priority patent/AU716894B2/en
Publication of WO1996030390A2 publication Critical patent/WO1996030390A2/en
Publication of WO1996030390A3 publication Critical patent/WO1996030390A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Abstract

Methods for the preparation of the 19-norprogesterone of formula (I) and its intermediates, in crystalline and amorphous forms.
PCT/US1996/003660 1995-03-30 1996-03-18 METHOD FOR PREPARING 17α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE METHOD, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES. WO1996030390A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP96909749A EP0817793A2 (en) 1995-03-30 1996-03-18 Method for preparing 17alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the method, and methods for the preparation of such intermediates.
AU53145/96A AU716894B2 (en) 1995-03-30 1996-03-18 Method for preparing 17alpha-acetoxy-11beta-(4-N,N-dimethyla minophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the method, and methods for the preparation of such intermediates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/413,755 US5929262A (en) 1995-03-30 1995-03-30 Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US08/413,755 1995-03-30

Publications (2)

Publication Number Publication Date
WO1996030390A2 WO1996030390A2 (en) 1996-10-03
WO1996030390A3 true WO1996030390A3 (en) 1997-01-09

Family

ID=23638482

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/003660 WO1996030390A2 (en) 1995-03-30 1996-03-18 METHOD FOR PREPARING 17α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE METHOD, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES.

Country Status (5)

Country Link
US (1) US5929262A (en)
EP (1) EP0817793A2 (en)
AU (1) AU716894B2 (en)
CA (1) CA2216737A1 (en)
WO (1) WO1996030390A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE194358T1 (en) * 1996-05-01 2000-07-15 Us Gov Health & Human Serv 21-SUBSTITUTED PROGESTERONE DERIVATIVES AS ANTIGEGESGENS
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
US20090273641A1 (en) * 1997-07-15 2009-11-05 Silverbrook Research Pty Ltd Printhead IC With Ink Supply Channel For Multiple Nozzle Rows
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US5962444A (en) * 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP2033965A3 (en) * 2000-03-17 2012-09-19 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents
FR2826004B1 (en) * 2001-06-13 2008-03-28 Aventis Pharma Sa PROCESS FOR THE PREPARATION OF ESTROGENIC DERIVATIVES
DE10218103A1 (en) † 2002-04-23 2003-11-20 Boysen Friedrich Gmbh Co Kg Exhaust manifold for IC engines has solder connections between exhaust pipes and engine mounting flange, pipes and outer shell, and/or shell and flange, preventing inclusion of foreign bodies
ES2212912B1 (en) 2003-01-22 2005-10-01 Crystal Pharma, S.A. PROCEDURE FOR OBTAINING 17ALFA-ACETOXI-11BETA- (4-N, N-DIMETHYLAMINEPHENYL) -19-NORPREGNA-4,9-DIEN-3,20-DIONA.
AU2004217988C1 (en) 2003-02-28 2010-06-03 Southwest Foundation For Biomedical Research Method for preparing 17 alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
US20060247452A1 (en) * 2004-01-21 2006-11-02 Guisasola Luis Octavio S Method for obtaining 17sg(a)-acetoxy-11$g(b)-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione
HU227112B1 (en) * 2006-06-14 2010-07-28 Richter Gedeon Nyrt Industrial process for the synthesis of 17alpha-acetoxy-11betha-[4-(n,n-dimethyl-amino)-phenyl]-19-norpregna-4,9-diene-3,20-dione and the new intermediates of the process
WO2009050136A2 (en) 2007-10-17 2009-04-23 Laboratoire Hra Pharma Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
DK2419108T3 (en) 2009-04-14 2016-12-05 Hra Pharma Lab A method for on-demand control of conception,
US8426392B2 (en) 2009-12-09 2013-04-23 Laboratoire Hra-Pharma Method for providing emergency contraception
WO2011091892A1 (en) 2010-02-01 2011-08-04 Ulmann Andre A method for late post coital contraception using ulipristal acetate
WO2011091890A1 (en) 2010-02-01 2011-08-04 Laboratoire Hra-Pharma A method for post coital contraception in overweight for obese female subjects using ulipristal acetate
CN102241722B (en) * 2010-05-12 2015-11-25 杭州容立医药科技有限公司 A kind of purification process synthesizing progesterone receptor modulator gifted zafirlukast
CN102372760A (en) * 2010-08-12 2012-03-14 杭州容立医药科技有限公司 Synthesis method of progesterone receptor regulating agent ulipristal
EP2471537A1 (en) 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
CN102516345B (en) * 2011-11-01 2014-11-26 上海优拓医药科技有限公司 Preparation method of ulipristal acetate and key intermediate thereof
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
CN102295674B (en) * 2011-07-14 2013-04-10 四川大学 Method of acquiring high-purity 17 alpha-acetoxy-11 beta-(4-N, N-dimethylaminophenyl)-19-norpregna-4, 9-diene-3, 20-dione
CN102321141B (en) * 2011-07-22 2013-05-15 上海希迈医药科技有限公司 Amorphous substance of 17alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregn-4,9-diene-3,20-diketone and preparation method thereof
CN102344478B (en) * 2011-07-22 2013-08-07 上海希迈医药科技有限公司 Crystal of 17 alpha-acetoxyl group-11 beta-(4-N, N-dimethylamino phenyl)-19-norpregna-4, 9- diene-3, 20- ketone and preparation method thereof
CN103130862B (en) * 2011-11-30 2016-04-13 成都伊诺达博医药科技有限公司 The synthetic method of two (ethylenedioxy)-19-norpregna-5, the 9-diene-17-alcohol of CDB-2914 key intermediate 3,20-
CN106046099B (en) * 2012-01-19 2018-03-16 华润紫竹药业有限公司 Steroidal compounds and its production and use
CN104628806A (en) * 2012-01-19 2015-05-20 华润紫竹药业有限公司 Steroid compound and preparation method and application thereof
FR2987271B1 (en) 2012-02-28 2017-08-18 Hra Pharma Lab COMBINATION OF SELECTIVE PROGESTERONE RECEPTOR MODULATORS AND NON-STEROID ANTI-INFLAMMATORY DRUGS
EP2641602A1 (en) 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
CN103755765B (en) * 2012-04-17 2018-01-02 常州市第四制药厂有限公司 Polymorphic of CDB-2914 and preparation method thereof
CN102675395B (en) * 2012-04-17 2014-04-30 常州市第四制药厂有限公司 Polycrystal forms of ulipristal acetate and preparation method thereof
HUE037889T2 (en) 2012-05-25 2018-09-28 Hra Pharma Lab Ulipristal acetate for prevention and treatment of breast tumors
CN102702296B (en) * 2012-06-19 2014-09-03 山东诚创医药技术开发有限公司 Preparation method of cyclo-3,20-bi(1, 2-ethidene acetal)-17alpha-hydroxyl-17beta-acetyl-estra-5(10),9(11)-diene-3-ketone
US9643994B2 (en) 2012-09-28 2017-05-09 Aska Pharmaceutical Co., Ltd. Crystalline polymorphic form of ulipristal acetate
WO2014050105A1 (en) 2012-09-28 2014-04-03 Aska Pharmaceutical Co., Ltd. Amorphous ulipristal acetate
EP2900683B1 (en) * 2012-09-28 2018-03-14 ASKA Pharmaceutical Co., Ltd. Crystalline polymorphic form of ulipristal acetate
CN102875629B (en) * 2012-10-10 2014-11-19 苏州康润医药有限公司 Synthetic method of ulipristal acetate
WO2014060888A1 (en) 2012-10-18 2014-04-24 Lupin Limited Novel process and intermediate for preparation of ulipristal
CN102942612A (en) * 2012-10-30 2013-02-27 四川大学 Novel method for synthesizing ulipristal acetate
CN103073612B (en) * 2013-02-04 2015-11-04 山东大学 The preparation method of CDB-2914 key intermediate
AR095831A1 (en) 2013-04-10 2015-11-11 Preglem Sa MODULATORS OF USEFUL PROGESTERONE RECEPTORS IN THE UTERINE FIBROID THERAPY
HU230319B1 (en) 2013-10-01 2016-01-28 Richter Gedeon Nyrt. Industrial process for producing steroid derivatives
HU230788B1 (en) * 2013-12-16 2018-05-02 Richter Gedeon Nyrt Norsteroid intermediates and process for their preparation
CN103755763A (en) * 2013-12-30 2014-04-30 烟台东诚生化股份有限公司 Preparation method of 17alpha-acetoxyl-11beta-(4-(N, N-dimethylamino)-phenyl)-19-norpregna-4, 9-diene-3, 20-diketone
CN104861025A (en) * 2015-05-16 2015-08-26 南京海纳医药科技有限公司 Purification method of ulipristal acetate
CN105622702B (en) * 2016-01-19 2017-09-12 苏州卫生职业技术学院 A kind of preparation method of CDB-2914 key intermediate
CN109053846B (en) * 2018-08-14 2020-01-07 台州仙琚药业有限公司 Method for preparing ulipristal bisketal acetate

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2201287A1 (en) * 1972-09-27 1974-04-26 Roussel Uclaf Epoxidation using hexafluoroacetone hydroperoxide - for treatment of unsatd. cyclic cpds esp steroids
FR2215416A1 (en) * 1973-01-29 1974-08-23 Roussel Uclaf
EP0268400A1 (en) * 1986-11-05 1988-05-25 The Upjohn Company Steroidal 17alpha-silyl ethers and process to corticoids and progesterones
WO1989012448A1 (en) * 1988-06-23 1989-12-28 Research Triangle Institute 11beta-SUBSTITUTED PROGESTERONE ANALOGS
EP0531212A2 (en) * 1991-09-06 1993-03-10 Roussel Uclaf New process for the preparation of hydrocortison and new intermediates of this process
EP0676203A1 (en) * 1994-04-08 1995-10-11 Roussel Uclaf Pharmaceutical compositions of antiglucocorticoid compounds for treating or preventing symptoms of spontaneous or narcotic-induced withdrawal

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (en) * 1977-01-13 1978-08-11 Roussel Uclaf NEW 4,9-DIENIC 11B-SUBSTITUTE STEROID DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICINAL PRODUCTS
FR2377417A1 (en) * 1977-01-13 1978-08-11 Roussel Uclaf NEW STEROID DERIVATIVES SUBSTITUTED IN 11B, AS WELL AS THEIR PREPARATION PROCESS
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2528434B1 (en) * 1982-06-11 1985-07-19 Roussel Uclaf NOVEL 19-NOR STEROIDS SUBSTITUTED IN 11B AND POSSIBLY IN 2, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS A MEDICAMENT
FR2522328B1 (en) * 1982-03-01 1986-02-14 Roussel Uclaf NEW PRODUCTS DERIVED FROM THE STRUCTURE 3-CETO 4,9 19-NOR STEROIDS, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS
EP0116974B1 (en) * 1983-02-18 1986-10-29 Schering Aktiengesellschaft 11-beta-aryl-estradienes, process for their preparation and pharmaceutical compositions containing them
US4780461A (en) * 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
FR2552766B1 (en) * 1983-10-04 1987-06-26 Theramex NEW PROCESS FOR THE PREPARATION OF DERIVATIVES FROM THE 17 A-HYDROXY 19-NOR PROGESTERONE SERIES
US4585590A (en) * 1984-02-03 1986-04-29 The Upjohn Company Cyanohydrin process
US4831131A (en) * 1984-02-03 1989-05-16 The Upjohn Company 11β,17α-Dihydroxy-17β-cyano-androstanes
US4548748A (en) * 1984-02-03 1985-10-22 The Upjohn Company Cyanohydrin process
US4921638A (en) * 1986-11-05 1990-05-01 The Upjohn Company 17β-cyano-9α,17α-dihydroxyandrost-4-en-3-one
US5272140A (en) * 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
KR890701614A (en) * 1987-08-14 1989-12-21 로버어트 에이 아마테이지 Conversion of Steroidal 17-cyanohydrin to Corticoids
DE3822770A1 (en) * 1988-07-01 1990-01-04 Schering Ag 13-ALKYL-11SS-PHENYLGONANE
FR2643638B1 (en) * 1989-02-24 1991-06-14 Roussel Uclaf NOVEL 19-NOR STEROIDS HAVING IN THE 11BETA POSITION A CARBON CHAIN COMPRISING AN AMIDE OR CARBAMATE FUNCTION, THEIR PREPARATION METHOD AND INTERMEDIATES THEREOF, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE3915951C1 (en) * 1989-05-12 1990-09-13 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2201287A1 (en) * 1972-09-27 1974-04-26 Roussel Uclaf Epoxidation using hexafluoroacetone hydroperoxide - for treatment of unsatd. cyclic cpds esp steroids
FR2215416A1 (en) * 1973-01-29 1974-08-23 Roussel Uclaf
EP0268400A1 (en) * 1986-11-05 1988-05-25 The Upjohn Company Steroidal 17alpha-silyl ethers and process to corticoids and progesterones
WO1989012448A1 (en) * 1988-06-23 1989-12-28 Research Triangle Institute 11beta-SUBSTITUTED PROGESTERONE ANALOGS
EP0531212A2 (en) * 1991-09-06 1993-03-10 Roussel Uclaf New process for the preparation of hydrocortison and new intermediates of this process
EP0676203A1 (en) * 1994-04-08 1995-10-11 Roussel Uclaf Pharmaceutical compositions of antiglucocorticoid compounds for treating or preventing symptoms of spontaneous or narcotic-induced withdrawal

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ACOSTA K ET AL: "Oxidative demethylation of 4-substituted N,N-dimethylanilines with iodine and calcium oxide in the presence of methanol", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS, no. 17, 1994, LETCHWORTH GB, pages 1985 - 1986, XP002009128 *
COOK C E ET AL: "Reversal of activity profile in analogs of the antiprogestin RU 486: effect of a 16.alpha.-substituent on progestational (agonist) activity", LIFE SCI., vol. 52, no. 2, 1993, pages 155 - 162, XP002009131 *
POYSER N L ET AL: "A comparison of the pregnancy-terminating potencies of three anti-progestins in guinea pigs, and the effects of sulprostone", PROSTAGLANDINS, LEUKOTRIENES ESSENT. FATTY ACIDS, vol. 50, no. 5, 1994, pages 245 - 247, XP002009130 *
TEUTSCH G ET AL: "Regioselective base-catalyzed rearrangement of steroidal.alpha.,.beta.-unsaturated epoxides", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS, no. 18, 1974, LETCHWORTH GB, pages 763 - 764, XP002009126 *
TEUTSCH G ET AL: "Synthesis of the 10.beta.-ethynyl analog of hydrocortisone acetate", J. CHEM. RES., SYNOP., no. 4, 1981, pages 87, XP002009127 *
WANG C ET AL: "The anti-progestin CDB 2914 has no antifertility effect in male rats", CONTRACEPTION, vol. 51, no. 3, March 1995 (1995-03-01), pages 215 - 218, XP002009129 *
YANG SUMING ET AL: "Stereoselective Epoxidation of 5(10)-ene of 11.beta.-Functionated Steroids and Effect of 5(10)-Epoxy Group on Reaction of 11.beta.Substitute", HETEROCYCLES, vol. 40, no. 1, January 1995 (1995-01-01), AMSTERDAM NL, pages 205 - 212, XP002016065 *

Also Published As

Publication number Publication date
CA2216737A1 (en) 1996-10-03
EP0817793A2 (en) 1998-01-14
AU5314596A (en) 1996-10-16
WO1996030390A2 (en) 1996-10-03
AU716894B2 (en) 2000-03-09
US5929262A (en) 1999-07-27

Similar Documents

Publication Publication Date Title
WO1996030390A3 (en) METHOD FOR PREPARING 17α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE METHOD, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES.
WO2004078709A3 (en) METHOD FOR PREPARING 17 α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES THEREOF, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES
AU649472B2 (en) New pregna-1,4-diene-3,20-dione-16-17-acetal-21 esters, process for their preparation, compositions and method for the treatment of inflammatory conditions
AU3399797A (en) Method and kits for preparing multicomponent nucleic acid constructs
AU562739B2 (en) 3 keto delta4,9,19-nor steroid derivatives
AU7662896A (en) Method for the production of hybrid plants
WO1997027380A3 (en) Method for forming a window in a tubular and apparatus for use in said method
AU7275396A (en) Method and device for the deposit of at least one film of intrinsic microcrystalline or nanocrystalline hydrogenated silicon and photovoltaic cell obtained by this method
EP1142847A3 (en) Cement dispersant, method for production thereof, and cement composition using the dispersant
AU7697091A (en) Pressure-sensitive, adhesive-backed substrates and method for producing same
AU1101795A (en) Apparatus and method for securing buildings during high wind conditions
ZA964054B (en) Immunostimulating wound healing compositions and methods for preparing and using same.
AU7072596A (en) Method for preparing omega-aminoalkanoic acid derivatives from cycloalkanones
AU8354691A (en) Amorphous silicon solar cell and method for manufacturing the same
AU1607392A (en) Modified amorphous silicic acid, process for its preparation and anti-blocking agent
AU2914897A (en) Methods for producing and transforming cassave protoplasts
EP0776904A3 (en) Method for the preparation of steroid derivative ketal
AU5188696A (en) Apparatus and process for reducing the frequency and duration of apneic events
AU692710B2 (en) Intercalation compounds, method for preparing them and use thereof, particularly in pyrotechnics
AU6821796A (en) Contraceptive combined preparation, kits containing the same and contraceptive method using this combined preparation
HU9201190D0 (en) Method for producing new pregna-1,4-diene-3,20-dione derivatives
AU3835697A (en) Method for inhibiting the growth of mammalian cells
AU7642096A (en) Process for the preparation of 2-beta, 16-beta-diamino 3-alpha, 17-beta-diacloxy 5-alpha-androstanes, neuromuscular blocking agents with a steroidal structure
AU7265896A (en) Process and device for producing sweets, sweets produced by this process
AUPN702895A0 (en) Method and means for growing plants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

ENP Entry into the national phase

Ref document number: 2216737

Country of ref document: CA

Ref country code: CA

Ref document number: 2216737

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996909749

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996909749

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1996909749

Country of ref document: EP